Efficacy of oseltamivir treatment in influenza virus-infected obese mice.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
31 08 2023
Historique:
medline: 4 9 2023
pubmed: 21 6 2023
entrez: 21 6 2023
Statut: ppublish

Résumé

Obesity has been epidemiologically and empirically linked with more severe diseases upon influenza infection. To ameliorate severe disease, treatment with antivirals, such as the neuraminidase inhibitor oseltamivir, is suggested to begin within days of infection especially in high-risk hosts. However, this treatment can be poorly effective and may generate resistance variants within the treated host. Here, we hypothesized that obesity would reduce oseltamivir treatment effectiveness in the genetically obese mouse model. We demonstrated that oseltamivir treatment does not improve viral clearance in obese mice. While no traditional variants associated with oseltamivir resistance emerged, we did note that drug treatment failed to quench the viral population and did lead to phenotypic drug resistance

Identifiants

pubmed: 37341495
doi: 10.1128/mbio.00887-23
pmc: PMC10470499
doi:

Substances chimiques

Oseltamivir 20O93L6F9H
Antiviral Agents 0
Neuraminidase EC 3.2.1.18

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0088723

Subventions

Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID)
ID : HHSN27220140006C
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases (DIR, NIAID)
ID : R01AI140766

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Infect Dis. 1998 Nov;178(5):1257-62
pubmed: 9780244
Front Immunol. 2019 May 10;10:1071
pubmed: 31134099
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
J Infect Dis. 2011 Jan 15;203(2):168-74
pubmed: 21288815
J Virol. 2019 Jan 4;93(2):
pubmed: 30381485
Vaccine. 2009 Oct 23;27(45):6317-23
pubmed: 19840667
PLoS Pathog. 2013;9(5):e1003343
pubmed: 23717200
Antimicrob Agents Chemother. 2011 Dec;55(12):5640-5
pubmed: 21930881
Cochrane Database Syst Rev. 2014 Apr 10;(4):CD008965
pubmed: 24718923
Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:25-36
pubmed: 23279894
Pharmacogenomics J. 2020 Aug;20(4):613-620
pubmed: 32015454
Antimicrob Agents Chemother. 2014;58(3):1615-21
pubmed: 24366750
J Chem Theory Comput. 2016 Dec 13;12(12):6098-6108
pubmed: 27951676
J Infect Dis. 2012 Nov 15;206(10):1504-11
pubmed: 22966122
Biochem Biophys Res Commun. 2019 May 28;513(2):405-411
pubmed: 30967261
BMC Genomics. 2015 Feb 14;16:79
pubmed: 25758772
Emerg Med Pract. 2018 Dec;20(12):1-20
pubmed: 30476430
J Clin Virol. 2011 Oct;52(2):70-8
pubmed: 21684202
Methods Mol Biol. 2008;436:67-75
pubmed: 18370042
Br J Clin Pharmacol. 2016 Jun;81(6):1103-12
pubmed: 26810861
Ann Am Thorac Soc. 2017 Nov;14(Supplement_5):S406-S409
pubmed: 29161078
Influenza Other Respir Viruses. 2016 Nov;10(6):532-535
pubmed: 27442795
PLoS One. 2018 Jul 19;13(7):e0200849
pubmed: 30024940
Nucleic Acids Res. 2017 Jan 4;45(D1):D466-D474
pubmed: 27679478
Clin Infect Dis. 2019 Nov 13;69(11):1896-1902
pubmed: 30753349
Trends Microbiol. 2018 Sep;26(9):781-793
pubmed: 29534854
Viruses. 2015 Sep 14;7(9):4929-44
pubmed: 26389935
Infect Drug Resist. 2017 Apr 20;10:121-134
pubmed: 28458567
Influenza Other Respir Viruses. 2017 Jan;11(1):74-84
pubmed: 27426214
Antivir Chem Chemother. 1999 Jul;10(4):187-93
pubmed: 10480737
J Infect Dis. 2012 Jan 15;205(2):252-61
pubmed: 22147799
Curr Opin Pediatr. 2017 Jun;29(3):297-302
pubmed: 28346272
Curr Top Microbiol Immunol. 2014;385:359-75
pubmed: 24990620
Trends Microbiol. 2004 Sep;12(9):417-23
pubmed: 15337163
J Antimicrob Chemother. 2011 Sep;66(9):2083-91
pubmed: 21700623
Microbes Infect. 2010 Sep;12(10):778-83
pubmed: 20452454
Lancet. 2004 Aug 28-Sep 3;364(9436):759-65
pubmed: 15337401
J Med Virol. 2018 Feb;90(2):212-218
pubmed: 28892181
Curr Opin Infect Dis. 2018 Dec;31(6):520-526
pubmed: 30299356
Antiviral Res. 2014 Nov;111:112-20
pubmed: 25245230
mBio. 2020 Mar 3;11(2):
pubmed: 32127459

Auteurs

Rebekah Honce (R)

Department of Infectious Diseases, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.
Integrated Program in Biomedical Sciences, University of Tennessee Health Science Center , Memphis, Tennessee, USA.

Jeremy Jones (J)

Department of Infectious Diseases, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

Victoria A Meliopoulos (VA)

Department of Infectious Diseases, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

Brandi Livingston (B)

Department of Infectious Diseases, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

Bridgett Sharp (B)

Department of Infectious Diseases, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

Leonardo D Estrada (LD)

Department of Infectious Diseases, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

Lindsey Wang (L)

Preclinical Pharmacokinetic Shared Resource, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

William Caulfield (W)

Preclinical Pharmacokinetic Shared Resource, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

Burgess Freeman (B)

Preclinical Pharmacokinetic Shared Resource, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

Elena Govorkova (E)

Department of Infectious Diseases, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.

Stacey Schultz-Cherry (S)

Department of Infectious Diseases, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.
Integrated Program in Biomedical Sciences, University of Tennessee Health Science Center , Memphis, Tennessee, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH